Novel Hepatitis C virus replicon inhibitors: Synthesis and structure–activity relationships of fused pyrimidine derivatives
摘要:
The synthesis of several pyrido[2,3-d] pyrimidine and pyrimido[4,5-d] pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays. (C) 2012 Elsevier Ltd. All rights reserved.
Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
Novel Hepatitis C virus replicon inhibitors: Synthesis and structure–activity relationships of fused pyrimidine derivatives
作者:A. Chris Krueger、Darold L. Madigan、David W. Beno、David A. Betebenner、Robert Carrick、Brian E. Green、Wenping He、Dachun Liu、Clarence J. Maring、Keith F. McDaniel、Hongmei Mo、Akhteruzzaman Molla、Christopher E. Motter、Tami J. Pilot-Matias、Michael D. Tufano、Dale J. Kempf
DOI:10.1016/j.bmcl.2012.01.096
日期:2012.3
The synthesis of several pyrido[2,3-d] pyrimidine and pyrimido[4,5-d] pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays. (C) 2012 Elsevier Ltd. All rights reserved.